Advertisement

Breast Cancer Medications

Here's a list of the approved drugs to treat breast cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Arimidex
GENERIC NAME anastrozole
DRUG INDICATION

Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.

DRUG Aromasin
GENERIC NAME exemestane
DRUG INDICATION

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

DRUG Evista
GENERIC NAME raloxifene
DRUG INDICATION

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

DRUG Fareston
GENERIC NAME toremifene
DRUG INDICATION

Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.

DRUG Faslodex
GENERIC NAME fulvestrant
DRUG INDICATION

Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.

DRUG Femara
GENERIC NAME letrozole
DRUG INDICATION

Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.

DRUG Lupron
GENERIC NAME leuprolide
DRUG INDICATION

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

DRUG Tamoxifen
GENERIC NAME tamoxifen
DRUG INDICATION

Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Zoladex
GENERIC NAME goserelin
DRUG INDICATION

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Afinitor
GENERIC NAME everolimus
DRUG INDICATION

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

DRUG Enhertu
GENERIC NAME fam-trastuzumab deruxtecan-nxki
DRUG INDICATION

Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for people with inoperable or metastatic HER2-positive breast cancer who were previously treated with at least two other prior anti-HER2 inhibitors.

DRUG Herceptin
GENERIC NAME trastuzumab
DRUG INDICATION

Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer and gastric or esophageal carcinoma that overexpresses human epidermal growth factor receptor 2.

DRUG Ibrance
GENERIC NAME palbociclib
DRUG INDICATION

Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Kadcyla
GENERIC NAME ado-trastuzumab emtansine
DRUG INDICATION

Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.

DRUG Kisqali
GENERIC NAME ribociclib
DRUG INDICATION

Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Lynparza
GENERIC NAME olaparib
DRUG INDICATION

Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations.

DRUG Nerlynx
GENERIC NAME neratinib
DRUG INDICATION

Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

DRUG Perjeta
GENERIC NAME pertuzumab
DRUG INDICATION

Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

DRUG Phesgo
GENERIC NAME Pertuzumab/trastuzumab/hyaluronidase
DRUG INDICATION

Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a health care provider at home. It is approved for people with early or metastatic HER2-positive breast cancer.

DRUG Piqray
GENERIC NAME alpelisib
DRUG INDICATION

Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Talzenna
GENERIC NAME talazoparib
DRUG INDICATION

Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

DRUG Trodelvy
GENERIC NAME sacituzumab govitecan
DRUG INDICATION

Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer.

DRUG Tukysa
GENERIC NAME tucatinib
DRUG INDICATION

Tukysa is a kinase inhibitor approved for use in combination therapy for people with previously treated inoperable or metastatic HER2-positive breast cancer, including cancer that has spread to the brain.

DRUG Tykerb
GENERIC NAME lapatanib
DRUG INDICATION

Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.

DRUG Verzenio
GENERIC NAME abemaciclib
DRUG INDICATION

Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG INDICATION

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.


Advertisement